Form 4: Lisata Therapeutics Executive's Equity Awards & Sales

Lisata Therapeutics' SVP James Nisco reported the grant of restricted stock and stock options, alongside tax-related share dispositions.

Summary

• James Nisco, SVP, Fin/Treas, Chief Actg Off of Lisata Therapeutics, Inc. (LSTA), reported transactions on January 9, 2026.
• He was granted 15,000 restricted stock awards under the Issuer's 2018 Equity Incentive Compensation Plan, vesting in four equal installments: one-fourth on the grant date and one-fourth on each of the first, second, and third annual anniversaries of the grant date.
• He also acquired 7,000 stock options with an exercise price of $1.97, expiring on January 9, 2036, with a similar vesting schedule to the restricted stock.
• To cover tax liabilities on the vesting of restricted stock, Nisco disposed of a total of 6,180 shares of common stock at a price of $1.97 per share.
• Following these transactions, Nisco beneficially owns 32,311 shares of common stock (including 20,750 unvested restricted stock) and 7,000 stock options.

Sentiment

Score: 6

Explanation: The filing reports routine equity grants to an executive, which is generally positive for aligning management interests with shareholders. The associated tax-related share dispositions are a standard occurrence and do not indicate negative sentiment.

Positives

• Grant of 15,000 restricted stock awards aligns executive interests with shareholder value.
• Grant of 7,000 stock options provides long-term incentive for executive performance.

Negatives

• Disposition of 6,180 shares of common stock to cover tax liabilities, reducing direct share ownership.

Future Outlook

The restricted stock awards and stock options have a vesting schedule over three years, with one-fourth vesting annually after the initial grant date vesting. This indicates a future commitment and incentive structure for the reporting person.

Industry Context

This filing is a routine insider transaction report, reflecting compensation practices for executives. It does not provide information to analyze broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The grant of equity awards aligns the executive's interests with long-term shareholder value. The tax-related sales are a minor, routine event.
• Employees: Reflects the company's ongoing use of equity incentive plans for executive compensation.

Next Steps

• Future vesting of restricted stock awards on the first, second, and third annual anniversaries of January 9, 2026.
• Future vesting of stock options on the first, second, and third annual anniversaries of January 9, 2026.

Key Dates

Keywords

Lisata Therapeutics, LSTA, James Nisco, Form 4, SEC filing, insider transaction, restricted stock, stock options, equity incentive plan, tax withholding